GRI Bio Valuation
| GRI Etf | USD 0.29 0.02 7.65% |
GRI Bio seems to be undervalued based on Macroaxis valuation methodology. Our model calculates the value of GRI Bio from analyzing the entity fundamentals such as Return On Asset of -0.99, return on equity of -2.49, and Shares Outstanding of 2.52 M as well as examining its technical indicators and probability of bankruptcy.
Price Book 0.825 | Enterprise Value -2.3 M | Trailing PE 0.0186 |
Undervalued
Today
Please note that GRI Bio's price fluctuation is dangerous at this time. Calculation of the real value of GRI Bio is based on 3 months time horizon. Increasing GRI Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since GRI Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GRI Etf. However, GRI Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.29 | Real 3.08 | Target 22.5 | Hype 0.21 | Naive 0.97 |
The intrinsic value of GRI Bio's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence GRI Bio's stock price.
Estimating the potential upside or downside of GRI Bio helps investors to forecast how GRI etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GRI Bio more accurately as focusing exclusively on GRI Bio's fundamentals will not take into account other important factors: GRI Bio Total Value Analysis
GRI Bio is currently projected to have company total value of (2.33 M) with market capitalization of 4.25 M, debt of 119 K, and cash on hands of 183.82 M. The negative valuation of GRI Bio may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial commitments of the company both on and off balance sheet. Investors should carefully check all of the GRI Bio fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(2.33 M) | 4.25 M | 119 K | 183.82 M |
GRI Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GRI Bio has an asset utilization ratio of 392.72 percent. This signifies that the ETF is making $3.93 for each dollar of assets. An increasing asset utilization means that GRI Bio is more efficient with each dollar of assets it utilizes for everyday operations.GRI Bio Ownership Allocation
Roughly 98.04 (percent) of GRI Bio outstanding shares are held by general public with 0.01 % owned by insiders and only 1.95 pct. by outside corporations.GRI Bio Profitability Analysis
The company reported the last year's revenue of 22.54 M. Reported Net Loss for the year was (8.21 M) with profit before taxes, overhead, and interest of 0.About GRI Bio Valuation
An absolute valuation paradigm, as applied to GRI Etf, attempts to find the value of GRI Bio based on its fundamental and basic technical indicators. By analyzing GRI Bio's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of GRI Bio's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of GRI Bio. We calculate exposure to GRI Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GRI Bio's related companies.The investment seeks investment results that correspond generally to the performance, before the funds fees and expenses, of an index called the Cohen Steers Global Realty Majors Index. Cohen Steers is traded on Archipelago Exchange in USA.
Other Information on Investing in GRI Etf
GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.